Regeneron Covid-19 Trial Meets Primary Endpoint
30 September 2021 - 9:07PM
Dow Jones News
By Matt Grossman
Regeneron Pharmaceutical Inc. said Thursday that a clinical
trial of its REGN-COV candidate treatment for Covid-19 met the
drug's primary endpoint of significantly reducing viral load within
seven days in hospitalized patients.
Regeneron said that the drug, an antibody cocktail of
casirivimab and imdevimab, reduced the risk of death by 36% about a
month after treatment began in the study's patient population.
The Phase 2/3 trial included 1,197 patients hospitalized with
Covid-19, including some using supplemental oxygen and some who
weren't. Patients got either a placebo, or one of two dose levels
of REGN-COV.
REGN-COV hasn't been approved by the Food and Drug
Administration, but its use has been authorized in some high-risk
patients for treatment and post-exposure prophylaxis. Regeneron
shares climbed 2.2% in pre-market trading.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 30, 2021 06:52 ET (10:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
